NCT04612452View on ClinicalTrials.gov

The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART

CompletedOBSERVATIONAL
Enrollment

2,820

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

March 22, 2023

Study Completion Date

March 22, 2023

Conditions
HivDrug ResistancyVirologic Failure
Trial Locations (2)

Unknown

Lighthouse Trust, Lilongwe

CIDRZ, Lusaka

All Listed Sponsors
collaborator

University of KwaZulu

OTHER

collaborator

Lighthouse Trust

OTHER

collaborator

Centre for Infectious Disease Research in Zambia

OTHER

lead

University of Bern

OTHER

NCT04612452 - The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART | Biotech Hunter | Biotech Hunter